CANF Stock — Price, Charts & Analysis

Can-Fite BioPharma Ltd. (CANF) has no trailing P/E shown and a forward P/E of -12.89x. This places CANF in not enough valuation data territory based on the valuation data currently available on Worldtickers.

CANF trades with -12.89x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether CANF looks overvalued or undervalued.

CANF's P/E of -12.89x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

CANF's trailing EPS is -$10.84 and forward EPS is -$0.27.

EPS, or earnings per share, shows how much profit Can-Fite BioPharma Ltd. generated for each share. CANF's trailing EPS is -$10.84, and investors usually prefer EPS that is positive and growing over time.

Can-Fite BioPharma Ltd. has a market cap of $7.46M, making CANF a small-cap stock based on the current market value shown on Worldtickers.

CANF's latest stock price on Worldtickers is $3.48. The latest move is $0.03 or 0.87%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

CANF's quote includes a latest price of $3.48. The market open is $3.55. Previous close is $3.45. The intraday range is $3.40 to $3.49.

CANF is up in the latest quote, with a move of $0.03 or 0.87%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

CANF generated $405.00K in trailing revenue. Revenue growth is -43.30%, which helps show whether demand is expanding or slowing.

CANF's revenue growth is -43.30%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, CANF does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -$9.83M.

Gross margin is 100.00%. Margins show how efficiently Can-Fite BioPharma Ltd. turns revenue into profit.

Can-Fite BioPharma Ltd. carries $71.00K and holds $8.54M in cash.

CANF holds $8.54M on its balance sheet.

CANF's book value per share is $4.27.

Institutions hold 2.44% of CANF shares. Insiders hold 0.00% of shares. Ownership mix helps investors understand how much of Can-Fite BioPharma Ltd. is held by professional investors and company insiders.

CANF has 2.14M shares outstanding. Float shares are 2.14M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for CANF, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for CANF is -$0.27. Revenue growth is -43.30%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

CANF's trailing EPS is -$10.84. Forward EPS is -$0.27. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

CANF is in the Healthcare sector. Its earnings multiple is -12.89x. Its latest displayed growth metric is -43.30%. Compare these figures with sector peers before deciding whether Can-Fite BioPharma Ltd. is stronger or weaker than average.

CANF trades at $3.48. The stock trades at -12.89x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Can-Fite BioPharma Ltd.'s fundamentals.

CANF risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is -0.04, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

CANF should be compared with companies in Biotechnology. Its earnings multiple is -12.89x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Can-Fite BioPharma Ltd. (CANF) operates in Healthcare, specifically Biotechnology. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in

CANF trades on NYSE American. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

CANF stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Can-Fite BioPharma Ltd.'s official website listed on Worldtickers is www.canfite.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Can-Fite BioPharma Ltd. employs about 5 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Can-Fite BioPharma Ltd. is headquartered in Ramat Gan, Israel. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

CANF is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

CANF has traded between $2.56 and $13.60 over the past 52 weeks. At $3.48, it is 74.41% below the high and 35.94% above the low. The 52-week range helps gauge long-term price momentum.

CANF is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is $3.24 and its 200-day moving average is $4.20.

CANF's RSI is 54.91. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

CANF's latest RSI reading is 54.91, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for CANF is near $3.13. Key resistance is near $3.60. Breaks above resistance or below support can change the short-term technical setup.

CANF's nearest reported support level is $3.13. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

CANF's nearest reported resistance level is $3.60. A breakout above resistance can improve momentum, especially when volume confirms the move.

CANF trades about 1.44M shares daily on average. The latest displayed volume is 15.57K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

CANF's MACD is 0.02, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

CANF is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 54.91 (neutral). MACD is bullish. Nearest support is around $3.13. Resistance is around $3.60. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $3.31 (5.17% from price). MA50 is $3.24 (7.33% from price). MA200 is $4.20 (-17.06% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. CANF's MA20 is $3.31. MA50 is $3.24. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

CANF's pivot is near $3.46. Support is near $3.13. Resistance is near $3.60. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for CANF is near $3.14. The next upper resistance zone is near $3.68. These levels help define risk and possible follow-through zones after a breakout or breakdown.

CANF's Bollinger range is roughly $3.03 to $3.59. Band width is near 17.04%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

CANF's ATR-based typical daily range is about 6.15%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 15.57K shares. Average volume is about 1.44M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

CANF's all-time high shown on Worldtickers is $28,380.00. Its all-time low is $2.56. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

CANF has a beta of -0.04, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.